Biotron (BIT) and C14 appear to operate on a business model...

Biotron (BIT) and C14 appear to operate on a business model fundamentally built around delay. While these delays continuously erode shareholder value and produce no meaningful return on investment, they seem to benefit those managing both entities. For them, delay is not a liability—it’s an asset.

This model translates delay into a business advantage, effectively bypassing regulatory scrutiny. Inefficiency and inaction are not accidental—they function as tools that help deflect oversight and accountability. In this environment, shareholder interests are sidelined, while those in control continue to extract value under the cover of prolonged timelines and commercial secrecy.